Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities

Trends in Cancer

Volumn 2, Issue 2, 2016, Pages 95-109

  Antonioli, Luca ^a,b   Yegutkin, Gennady G ^c   Pacher, Pál ^d   Blandizzi, Corrado ^a   Haskó, György ^b  

^a UNIVERSITY OF PISA   (Italy)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TURKU   (Finland)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

adenosine; cancer; CD73; immunotherapy; tumor microenvironment

Indexed keywords

ADENOSINE; ECTO 5' NUCLEOTIDASE; MONOCLONAL ANTIBODY;

ANGIOGENESIS; CANCER CELL; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EXOSOME; EXTRACELLULAR MATRIX; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; LYMPHANGIOGENESIS; LYMPHOCYTIC INFILTRATION; MACROPHAGE; METASTASIS; MOLECULAR BIOLOGY; REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84959262007     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.01.003     Document Type: Review

References (161)

1. C.E. Weber, and P.C. Kuo The tumor microenvironment Surg. Oncol. 21 2012 172 177
2. R.A. Cairns, and et al. Regulation of cancer cell metabolism Nat. Rev. Cancer 11 2011 85 95
3. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
4. L. Antonioli, and et al. Immunity, inflammation and cancer: a leading role for adenosine Nat. Rev. Cancer 13 2013 842 857
5. L. Antonioli, and et al. CD39 and CD73 in immunity and inflammation Trends Mol. Med. 19 2013 355 367
6. G.G. Yegutkin Enzymes involved in metabolism of extracellular nucleotides and nucleosides: functional implications and measurement of activities Crit. Rev. Biochem. Mol. Biol. 49 2014 473 497
7. B. Zhang CD73: a novel target for cancer immunotherapy Cancer Res. 70 2010 6407 6411
8. P.A. Beavis, and et al. CD73: a potent suppressor of antitumor immune responses Trends Immunol. 33 2012 231 237
9. Z.W. Gao, and et al. The roles of CD73 in cancer Biomed. Res. Int. 2014 2014 460654
10. B. Zhang Opportunities and challenges for anti-CD73 cancer therapy Immunotherapy 4 2012 861 865
11. B. Allard, and et al. Anti-CD73 therapy impairs tumor angiogenesis Int. J. Cancer 134 2014 1466 1473
12. S. Cushman, and et al. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance) Clin. Cancer. Res. 21 2015 1078 1086
13. G.G. Yegutkin, and et al. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression Eur. J. Immunol. 41 2011 1231 1241
14. J. Stagg, and et al. CD73-deficient mice are resistant to carcinogenesis Cancer Res. 72 2012 2190 2196
15. J. Stagg, and et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis Cancer Res. 71 2011 2892 2900
16. F. Figueiro, and et al. A monastrol-derived compound, LaSOM 63, inhibits ecto-5′nucleotidase/CD73 activity and induces apoptotic cell death of glioma cell lines Anticancer Res. 34 2014 1837 1842
17. S.F. Hausler, and et al. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion Am. J. Transl. Res. 6 2014 129 139
18. P. Koszalka, and et al. Inhibition of CD73 stimulates the migration and invasion of B16F10 melanoma cells in vitro, but results in impaired angiogenesis and reduced melanoma growth in vivo Oncol. Rep. 31 2014 819 827
19. M.G. Terp, and et al. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells J. Immunol. 191 2013 4165 4173
20. C. Quezada, and et al. 5′-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells J. Cell. Physiol. 228 2013 602 608
21. G. Forte, and et al. Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma J. Immunol. 189 2012 2226 2233
22. X. Zhi, and et al. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells Cancer Sci. 101 2010 2561 2569
23. J. Stagg, and et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis Proc. Natl. Acad. Sci. U.S.A. 107 2010 1547 1552
24. S. Loi, and et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer Proc. Natl. Acad. Sci. U.S.A. 110 2013 11091 11096
25. B. Allard, and et al. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs Clin. Cancer Res. 19 2013 5626 5635
26. T.F. Gajewski, and et al. Innate and adaptive immune cells in the tumor microenvironment Nat. Immunol. 14 2013 1014 1022
27. S. Deaglio, and et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression J. Exp. Med. 204 2007 1257 1265
28. D. Eichin, and et al. CD73 activity is dispensable for the polarization of M2 macrophages PLoS ONE 10 2015 e0134721
29. F. Chalmin, and et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression Immunity 36 2012 362 373
30. C. Oelkrug, and J.M. Ramage Enhancement of T cell recruitment and infiltration into tumours Clin. Exp. Immunol. 178 2014 1 8
31. B. Crimeen-Irwin, and et al. Failure of immune homeostasis - the consequences of under and over reactivity Curr. Drug. Targets Immune. Endocr. Metabol. Disord. 5 2005 413 422
32. M.Q. Li, and et al. CD4+Foxp3+ regulatory T cell differentiation mediated by endometrial stromal cell-derived TECK promotes the growth and invasion of endometriotic lesions Cell Death Dis. 5 2014 e1436
33. M. Salmi, and S. Jalkanen Host CD73 impairs anti-tumor immunity Oncoimmunology 1 2012 247 248
34. L. Wang, and et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice J. Clin. Invest. 121 2011 2371 2382
35. P.J. Schuler, and et al. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells Clin. Exp. Immunol. 177 2014 531 543
36. F.S. Regateiro, and et al. CD73 and adenosine generation in the creation of regulatory microenvironments Clin. Exp. Immunol. 171 2013 1 7
37. A. Ohta, and et al. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments J. Immunol. 183 2009 5487 5493
38. M. Romio, and et al. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells Am. J. Physiol. Cell Physiol. 301 2011 C530 C539
39. P.E. Zarek, and et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells Blood 111 2008 251 259
40. H. Zeng, and et al. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function Nature 499 2013 485 490
41. R.J. Martinez, and et al. Arthritogenic self-reactive CD4+ T cells acquire an FR4hiCD73hi anergic state in the presence of Foxp3+ regulatory T cells J. Immunol. 188 2012 170 181
42. D. Jin, and et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression Cancer Res. 70 2010 2245 2255
43. L. Airas, and et al. CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73 J. Exp. Med. 182 1995 1603 1608
44. L. Airas, and et al. CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism J. Immunol. 165 2000 5411 5417
45. Y. Ma, and et al. Dendritic cells in the cancer microenvironment J. Cancer 4 2013 36 44
46. C. Cekic, and et al. Adenosine A2B receptor blockade slows growth of bladder and breast tumors J. Immunol. 188 2012 198 205
47. C. Cekic, and et al. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment Cancer Res. 74 2014 7250 7259
48. N.B. Hao, and et al. Macrophages in tumor microenvironments and the progression of tumors Clin. Dev. Immunol. 2012 2012 948098
49. R.F. Zanin, and et al. Differential macrophage activation alters the expression profile of NTPDase and ecto-5′-nucleotidase PLoS ONE 7 2012 e31205
50. B. Csoka, and et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors FASEB J. 26 2012 376 386
51. B. Koscso, and et al. Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages J. Leukoc. Biol. 94 2013 1309 1315
52. B. Csoka, and et al. A2B adenosine receptors prevent insulin resistance by inhibiting adipose tissue inflammation via maintaining alternative macrophage activation Diabetes 63 2014 850 866
53. C.J. Ferrante, and et al. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Ralpha) signaling Inflammation 36 2013 921 931
54. G. Hasko, and et al. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice J. Immunol. 157 1996 4634 4640
55. Z.H. Nemeth, and et al. Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism J. Immunol. 175 2005 8260 8270
56. G. Hasko, and et al. Adenosine inhibits IL-12 and TNF- [alpha] production via adenosine A2a receptor-dependent and independent mechanisms FASEB J. 14 2000 2065 2074
57. S. Stadler, and et al. New therapeutic options for advanced non-resectable malignant melanoma Adv. Med. Sci. 60 2014 83 88
58. S.L. Topalian, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med. 366 2012 2443 2454
59. D.I. Gabrilovich, and S. Nagaraj Myeloid-derived suppressor cells as regulators of the immune system Nat. Rev. Immunol. 9 2009 162 174
60. S.V. Ryzhov, and et al. Role of TGF-beta signaling in generation of CD39+CD73+ myeloid cells in tumors J. Immunol. 193 2014 3155 3164
61. J.E. Talmadge, and D.I. Gabrilovich History of myeloid-derived suppressor cells Nat. Rev. Cancer 13 2013 739 752
62. S. Ryzhov, and et al. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells J. Immunol. 187 2011 6120 6129
63. S. Madar, and et al. 'Cancer associated fibroblasts' - more than meets the eye Trends Mol. Med. 19 2013 447 453
64. P. Lu, and et al. The extracellular matrix: a dynamic niche in cancer progression J. Cell. Biol. 196 2012 395 406
65. H. Salmon, and et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors J. Clin. Invest. 122 2012 899 910
66. V. Paunescu, and et al. Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences J. Cell. Mol. Med. 15 2011 635 646
67. R. Huang, and et al. CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients PLoS ONE 9 2014 e112209
68. K.H. Kruger, and et al. Expression of ecto-5′-nucleotidase (CD73) in normal mammary gland and in breast carcinoma Br. J. Cancer 63 1991 114 118
69. B. Zhang, and et al. The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma Tumour Biol. 36 2015 5459 5466
70. X.R. Wu, and et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer J. Surg. Oncol. 106 2012 130 137
71. M. Turcotte, and et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer Cancer Res. 75 2015 4494 4503
72. I.S. Hong, and et al. Mesenchymal stem cells and cancer: friends or enemies? Mutat. Res. Fundam. Mol. Mech. Mutagen. 768 2014 98 106
73. F. Liotta, and et al. Mesenchymal stem cells are enriched in head neck squamous cell carcinoma, correlates with tumour size and inhibit T-cell proliferation Br. J. Cancer 112 2015 745 754
74. S. Amarnath, and et al. Bone marrow derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo Stem Cells 33 2014 1200 1212
75. A.M. Carothers, and et al. Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors Cancer Res. 72 2012 346 355
76. S. Tanabe Role of mesenchymal stem cells in cell life and their signaling World. J. Stem. Cells 6 2014 24 32
77. R. Haddad, and F. Saldanha-Araujo Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: what do we know so far? Biomed. Res. Int. 2014 216806
78. S. Scarfi Purinergic receptors and nucleotide processing ectoenzymes: their roles in regulating mesenchymal stem cell functions World. J. Stem Cells 6 2014 153 162
79. L. Antonioli, and et al. CD39 and CD73 in immunity and inflammation Trends. Mol. Med. 19 2013 355 367
80. X. Zhou, and et al. Effects of ecto-5′-nucleotidase on human breast cancer cell growth in vitro and in vivo Oncol. Rep. 17 2007 1341 1346
81. X. Zhi, and et al. RNA interference of ecto-5′-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion Clin. Exp. Metastasis 24 2007 439 448
82. E. Braganhol, and et al. Ecto-5′-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line Biochim. Biophys. Acta 1770 2007 1352 1359
83. L. Bavaresco, and et al. The role of ecto-5′-nucleotidase/CD73 in glioma cell line proliferation Mol. Cell. Biochem. 319 2008 61 68
84. S. Serra, and et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death Blood 118 2011 6141 6152
85. B. Allard, and et al. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth J. Biomed. Biotechnol. 2012 2012 485156
86. L. Wang, and et al. Ecto-5′-nucleotidase (CD73) promotes tumor angiogenesis Clin. Exp. Metastasis 30 2013 671 680
87. S. Burghoff, and et al. Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice BMC Cancer 14 2014 898
88. L. Eklund, and et al. Mouse models for studying angiogenesis and lymphangiogenesis in cancer Mol. Oncol. 7 2013 259 282
89. S.A. Stacker The role of tumor lymphangiogenesis in metastatic spread FASEB. J. 16 2002 922 934
90. G.G. Yegutkin, and et al. Ecto-5′-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature Eur. J. Immunol. 45 2015 562 573
91. A. Algars, and et al. Different role of CD73 in leukocyte trafficking via blood and lymph vessels Blood 117 2011 4387 4393
92. M. Pancione, and et al. Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis J. Immunol. Res. 2014 2014 686879
93. L. Qin, and et al. Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis Immunotherapy 6 2014 19 21
94. P.A. Beavis, and et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors Proc. Natl. Acad. Sci. U.S.A. 110 2013 14711 14716
95. Q. Yang, and et al. Overexpression of CD73 in prostate cancer is associated with lymph node metastasis Pathol. Oncol. Res. 19 2013 811 814
96. A.R. Cappellari, and et al. Characterization of ectonucleotidases in human medulloblastoma cell lines: ecto-5′NT/CD73 in metastasis as potential prognostic factor PLoS ONE 7 2012 e47468
97. B. Zhang CD73 promotes tumor growth and metastasis Oncoimmunology 1 2012 67 70
98. L. Wang, and et al. Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells J. Cancer Res. Clin. Oncol. 134 2008 365 372
99. R. Sadej, and et al. Ecto-5′-nucleotidase (eN, CD73) is coexpressed with metastasis promoting antigens in human melanoma cells Nucleosides Nucleotides Nucleic Acids 25 2006 1119 1123
100. P. Zhou, and et al. Overexpression of Ecto-5′-nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix Cancer Biol. Ther. 6 2007 426 431
101. H.A. Goubran, and et al. Regulation of tumor growth and metastasis: the role of tumor microenvironment Cancer Growth Metastasis 7 2014 9 18
102. L. Xiong, and et al. NT5E and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer Cell. Tissue Res. 355 2014 365 374
103. F. Chen, and et al. New horizons in tumor microenvironment biology: challenges and opportunities BMC Med. 13 2015 45
104. S. Bhattarai, and et al. alpha,beta-Methylene-ADP (AOPCP) derivatives and analogues: development of potent and selective ecto-5′-nucleotidase (CD73) inhibitors J. Med. Chem. 58 2015 6248 6263
105. A. Young, and et al. Targeting cancer-derived adenosine: new therapeutic approaches Cancer Discov. 4 2014 879 888
106. S.P. Colgan, and et al. Physiological roles for ecto-5′-nucleotidase (CD73) Purinergic Signal. 2 2006 351 360
107. M.W. Teng, and et al. Classifying cancers based on T-cell infiltration and PD-L1 Cancer Res. 75 2015 2139 2145
108. K. Pietras, and A. Ostman Hallmarks of cancer: interactions with the tumor stroma Exp. Cell Res. 316 2010 1324 1331
109. H. Zimmermann 5′-Nucleotidase: molecular structure and functional aspects Biochem. J. 285 1992 345 365
110. K. Synnestvedt, and et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia J. Clin. Invest. 110 2002 993 1002
111. M.L. Hart, and et al. Hypoxia-inducible factor-1alpha-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5′-nucleotidase (CD73) and the A2B adenosine receptor J. Immunol. 186 2011 4367 4374
112. A. Robinson, and et al. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition Gastroenterology 134 2008 145 155
113. H.K. Eltzschig, and et al. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases Nat. Rev. Drug. Discov. 13 2014 852 869
114. J. Kiss, and et al. IFN-beta protects from vascular leakage via up-regulation of CD73 Eur. J. Immunol. 37 2007 3334 3338
115. N. Strater Ecto-5′-nucleotidase: Structure function relationships Purinergic Signal. 2 2006 343 350
116. D.P. Heuts, and et al. Crystal structure of a soluble form of human CD73 with ecto-5′-nucleotidase activity Chembiochem 13 2012 2384 2391
117. G.G. Yegutkin Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade Biochim. Biophys. Acta 1783 2008 673 694
118. H.K. Eltzschig, and et al. Purinergic signaling during inflammation N. Engl. J. Med. 367 2012 2322 2333
119. T. Vaisitti, and et al. NAD+-metabolizing ecto-enzymes shape tumor-host interactions: the chronic lymphocytic leukemia model FEBS Lett. 585 2011 1514 1520
120. F. Haag, and et al. Extracellular NAD and ATP: partners in immune cell modulation Purinergic Signal. 3 2007 71 81
121. A.L. Horenstein, and et al. A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes Oncoimmunology 2 2013 e26246
122. R. Sadej, and A.C. Skladanowski Dual, enzymatic and non-enzymatic, function of ecto-5′-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells Acta Biochim. Pol. 59 2012 647 652
123. J. Stella, and et al. Differential ectonucleotidase expression in human bladder cancer cell lines Urol. Oncol. 28 2010 260 267
124. X. Zhi, and et al. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer IUBMB Life 64 2012 911 920
125. B. Zhang, and et al. The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma Tumour. Biol. 36 2015 5459 5466
126. S. Xu, and et al. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas Neuro. Oncol. 15 2013 1160 1172
127. M. Mandapathil, and et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer Clin. Cancer Res. 15 2009 6348 6357
128. R. Sadej, and et al. Expression of ecto-5′-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma Melanoma Res. 16 2006 213 222
129. H.K. Oh, and et al. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration J. Gynecol. Oncol. 2012 23274 23281
130. R.S. Haun, and et al. Bioorthogonal labeling cell-surface proteins expressed in pancreatic cancer cells to identify potential diagnostic/therapeutic biomarkers Cancer Biol. Ther. 16 2015 1557 1565
131. T. Kondo, and et al. Expression of CD73 and its ecto-5′-nucleotidase activity are elevated in papillary thyroid carcinomas Histopathology 48 2006 612 614
132. C.L. Chaffer, and R.A. Weinberg A perspective on cancer cell metastasis Science 331 2011 1559 1564
133. R.R. Langley, and I.J. Fidler The seed and soil hypothesis revisited - the role of tumor-stroma interactions in metastasis to different organs Int. J. Cancer 128 2011 2527 2535
134. C. Kahlert, and R. Kalluri Exosomes in tumor microenvironment influence cancer progression and metastasis J. Mol. Med. (Berl) 91 2013 431 437
135. C. Braicu, and et al. Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death Differ. 22 2015 34 45
136. C. Yang, and P.D. Robbins The roles of tumor-derived exosomes in cancer pathogenesis Clin. Dev. Immunol 2011 2011 842849
137. A. Clayton, and et al. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production J. Immunol. 187 2011 676 683
138. L.A. Smyth, and et al. CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+ T cells contributes to their regulatory function Eur. J. Immunol. 43 2013 2430 2440
139. G.G. Yegutkin, and et al. Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 activities FASEB J. 26 2012 3875 3883
140. B. Allard, and et al. Anti-CD73 therapy impairs tumor angiogenesis Int. J. Cancer 134 2013 1466 1473
141. S. Rust, and et al. Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type Mol. Cancer 12 2013 11
142. N. Liu, and et al. CD73 as a novel prognostic biomarker for human colorectal cancer J. Surg. Oncol. 106 2012 918 919
143. X.X. Lu, and et al. Expression and clinical significance of CD73 and hypoxia-inducible factor-1alpha in gastric carcinoma World. J. Gastroenterol. 19 2013 1912 1918
144. H. Wang, and et al. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity Br. J. Cancer 106 2012 1446 1452
145. E. Wieten, and et al. CD73 (5′-nucleotidase) expression has no prognostic value in children with acute lymphoblastic leukemia Leukemia 25 2011 1374 1376
146. A. Supernat, and et al. CD73 expression as a potential marker of good prognosis in breast carcinoma Appl. Immunohistochem. Mol. Morphol. 20 2012 103 107
147. C. Holohan, and et al. Cancer drug resistance: an evolving paradigm Nat. Rev. Cancer 13 2013 714 726
148. P. Ujhazy, and et al. Evidence for the involvement of ecto-5′-nucleotidase (CD73) in drug resistance Int. J. Cancer 68 1996 493 500
149. W. Garrido, and et al. FK506 confers chemosensitivity to anticancer drugs in glioblastoma multiforme cells by decreasing the expression of the multiple resistance-associated protein-1 Biochem. Biophys. Res. Commun. 411 2011 62 68
150. P. Ujhazy, and et al. Ecto-5′-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin Int. J. Cancer 59 1994 83 93
151. S.M. Cushman, and et al. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance) Clin. Cancer Res. 21 2015 1078 1086
152. J.M. Kirkwood, and et al. Next generation of immunotherapy for melanoma J. Clin. Oncol. 26 2008 3445 3455
153. K. Palucka, and J. Banchereau Dendritic-cell-based therapeutic cancer vaccines Immunity 39 2013 38 48
154. C. Larocca, and J. Schlom Viral vector-based therapeutic cancer vaccines Cancer J. 17 2011 359 371
155. M.A. McNamara, and et al. RNA-based vaccines in cancer immunotherapy J. Immunol. Res. 2015 2015 794528
156. C.L. Slingluff Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J. 17 2011 343 350
157. D.L. Bartlett, and et al. Oncolytic viruses as therapeutic cancer vaccines Mol. Cancer 12 2013 103
158. R. Wu, and et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook Cancer J. 18 2012 160 175
159. H.J. Stauss, and et al. Cancer gene therapy with T cell receptors and chimeric antigen receptors Curr. Opin. Pharmacol. 24 2015 113 118
160. G. Dotti, and et al. Design and development of therapies using chimeric antigen receptor-expressing T cells Immunol. Rev. 257 2014 107 126
161. I. Melero, and et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer Nat. Rev. Cancer 15 2015 457 472